glp-1 receptor agonists effectiveness comparison Comparative of on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis PDB-101: Molecule of the Month:

MPTP-induced motor impairments were also alleviated

PubReader Cite Cite Close Download Citation Close XML Download Figure Fig

Monlunabant (INV-202) Monlunabant is a peripherally acting cannabinoid receptor-1 (CB1) inverse agonist administered orally once a day

Theories on how GLP-1 can prevent beta cell apoptosis, and possibly cause beta cell regeneration and proliferation: GLP-1 inhibits apoptosis Farilla and colleagues, demonstrated in their studies with the isolated human islets, which were separated into groups of those with and without GLP-1

These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent

Nausea, vomiting, diarrhea, and reduced appetite typically occur during dose escalation